Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.

Results View source PDF Explain this filing

VENUSREM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+10.0%Reaction day

₹362.40

prior close

₹393.50

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%+10.0% vs market

Pharmaceuticals peers, median of 147sector+0.1%+9.8% vs sector

On the reaction day the stock moved 10.0 pts more than Nifty Microcap 250 and 9.8 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.7

10m

+3.9

15m

+4.4

30m

+3.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+10.0-0.1+10.0+0.1+9.8

Next day

+9.0+0.2+8.7-0.0+9.0

+12.3+0.6+11.7+0.8+11.5

+20.3+0.9+19.4+0.3+20.0

+26.9+1.0+25.9+0.0+26.9

+26.4+0.7+25.6-0.7+27.0

+20.6+1.8+18.8-0.1+20.6

15d

+20.9+1.7+19.2-0.9+21.8

+26.1+3.1+23.0-0.8+26.9

+43.2+1.7+41.5+0.4+42.8

+26.9-1.0+28.0-3.0+29.9

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Venus Remedies Limited has submitted its audited financial results for the quarter and full year ended March 31, 2025 to the stock exchange. The filing is in compliance with SEBI's listing requirements for periodic disclosure of financial performance. No specific revenue, profit, or margin figures are detailed in the headline of this announcement.

Likely market impact

This is a routine regulatory filing; investors should review the detailed results document for actual revenue, profit, and margin performance before drawing any conclusions about the company's financial health.